Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [K67/25] to Caspr2/CNTNAP2
- Suitable for: IHC-P
- Reacts with: Human
Product nameAnti-Caspr2/CNTNAP2 antibody [K67/25]
See all Caspr2/CNTNAP2 primary antibodies
DescriptionMouse monoclonal [K67/25] to Caspr2/CNTNAP2
Tested applicationsSuitable for: IHC-Pmore details
Unsuitable for: Flow Cyt,ICC/IF,IP or WB
Species reactivityReacts with: Human
- IHC-P: Human cerebrum tissue.
This antibody clone is manufactured by Abcam. If you require a different buffer formulation or a particular conjugate for your experiments, please contact email@example.com.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab252534 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 0.45 µg/ml. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.|
FunctionMay play a role in the formation of functional distinct domains critical for saltatory conduction of nerve impulses in myelinated nerve fibers. Seems to demarcate the juxtaparanodal region of the axo-glial junction.
Tissue specificityPredominantly expressed in nervous system.
Involvement in diseaseDefects in CNTNAP2 are the cause of cortical dysplasia-focal epilepsy syndrome (CDFES) [MIM:610042]. Affected individuals manifest cortical dysplasia, focal epilepsy, relative macrocephaly, and diminished deep-tendon reflexes. Intractable focal seizures begin in early childhood, after which language regression, hyperactivity, impulsive and aggressive behavior, and mental retardation develop.
Genetic variations in CNTNAP2 influences susceptibility to autism type 15 (AUTS15) [MIM:612100]. Autism is a neurodevelopmental disorder characterized by disturbance in language, perception and socialization. The disorder is classically defined by a triad of limited or absent verbal communication, a lack of reciprocal social interaction or responsiveness, and restricted, stereotypical, and ritualized patterns of interests and behavior.
Note=A chromosomal aberration involving CNTNAP2 is found in a patient with autism spectrum disorder. Paracentric inversion 46,XY,inv(7)(q11.22;q35). The inversion breakpoints disrupt the genes AUTS2 and CNTNAP2.
Sequence similaritiesBelongs to the neurexin family.
Contains 2 EGF-like domains.
Contains 1 F5/8 type C domain.
Contains 1 fibrinogen C-terminal domain.
Contains 4 laminin G-like domains.
- Information by UniProt
- AUTS15 antibody
- CDFE antibody
- Cell recognition molecule Caspr2 antibody
Immunohistochemical analysis of paraffin-embedded human cerebrum tissue labeling Caspr2/CNTNAP2 with ab252534 at 0.45µg/ml, followed by a ready to use secondary antibody. Positive staining on human cerebrum is observed. Counter stained with hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is a ready to use secondary.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
The section was incubated with ab252534 for 30 mins at room temperature.
The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab252534 has not yet been referenced specifically in any publications.